Guangzhou Innogen Pharmaceutical Group Co Ltd (hkse:02591) Share Price

Company Profile

Business description
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize an innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize innovative therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates targeting diabetes and other metabolic diseases.
Contact
No. 2 Tengfei Second Street
Room 409, Building H Self-numbered Creative Building
China-Singapore Guangzhou Knowledge City
Huangpu District, Guangdong Province
Guangzhou
CHN
https://www.innogenpharm.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
96

Recommended

Here’s a wide-moat company with strong secular tailwinds in a promising industry—and an attractive stock price, too.

Malik Ahmed Khan, CFA | 08 January 2026

Wagering continues to be challenged in Australia.

Angus Hewitt, CFA | 08 January 2026

Rising inflation is the fly in the ointment.

Simonelle Mody | 08 January 2026

Index	Last price	Change	% Change
All Ordinaries	9,045.90	27.80	-0.31%
CAC 40	8,325.18	91.26	1.11%
DAX 40	25,261.64	134.18	0.53%
Dow JONES (US)	49,504.07	237.96	0.48%
FTSE 100	10,108.32	63.63	0.63%
HKSE	26,231.79	82.48	0.32%
NASDAQ	23,671.35	191.33	0.81%
Nikkei 225	51,939.89	822.63	1.61%
NZX 50 Index	13,696.25	20.61	-0.15%
S&P 500	6,966.28	44.82	0.65%
S&P/ASX 200	8,717.80	29.10	-0.33%
SSE Composite Index	4,120.43	37.45	0.92%